Clinical trials: Circulating Tumor Cells

First or Second Line HER2-negative Breast Cancer, Metastatic Disease Without Bone Metastasis

Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients

• Completed
• Age: 18 years and older
• Phase 4
• Injection or infusion
• Results posted

This study will evaluate zoledronic acid's anti-cancer effects and Circulating Tumor Cell (CTCs) measurements in patients with HER2-negative metastatic breast cancer without bone metastasis.

Trial name

MACS1295 (NCT01129336)

Testing

Zoledronic acid, Standard Therapy

Where

33 sites in United States

Volunteers

44 people

Sponsor

Novartis Pharmaceuticals